{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T05:12:55Z","timestamp":1722661975129},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T00:00:00Z","timestamp":1522195200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s12185-018-2434-2","type":"journal-article","created":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T09:58:12Z","timestamp":1522231092000},"page":"22-29","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Perioperative safety and hemostatic efficacy of Advate\u00ae in patients with hemophilia A in a postmarketing surveillance in Japan"],"prefix":"10.1007","volume":"108","author":[{"given":"Keiji","family":"Nogami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Takedani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Midori","family":"Shima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junki","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Taki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyuki","family":"Fukutake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhiko","family":"Uchikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morio","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Engl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Shirahata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,28]]},"reference":[{"key":"2434_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1365-2516.2004.00932.x","volume":"10","author":"MD Tarantino","year":"2004","unstructured":"Tarantino MD, Collins PW, Hay CR, Shapiro AD, Gruppo RA, Berntorp E, et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma\/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia. 2004;10:428\u201337.","journal-title":"Haemophilia."},{"key":"2434_CR2","doi-asserted-by":"crossref","unstructured":"Blanchette VS, Shapiro AD, Liesner RJ, et al. on behalf of the rAHF-PEM Clinical Study Group. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated paediatric patients. J Thromb Haemost 2008; 6:1319-26.","DOI":"10.1111\/j.1538-7836.2008.03032.x"},{"key":"2434_CR3","doi-asserted-by":"publisher","first-page":"987","DOI":"10.2165\/11207480-000000000-00000","volume":"72","author":"S Dhillon","year":"2012","unstructured":"Dhillon S. Octocog Alfa, Antihaemophilic Factor (Recombinant), Plasma\/Albumin Free Method (ADVATE\u00ae) A Review of its use in the management of patients with haemophilia A. Drugs. 2012;72:987\u20131007.","journal-title":"Drugs"},{"key":"2434_CR4","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/j.1365-2141.2007.06490.x","volume":"136","author":"L Raffini","year":"2007","unstructured":"Raffini L, Manno C. Modern management of haemophilic arthropathy. Br J Haematol. 2007;136:777\u201387.","journal-title":"Br J Haematol"},{"key":"2434_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000660","author":"S Tabibian","year":"2017","unstructured":"Tabibian S, Motlagh H, Naderi M, Dorgalaleh A. Intracranial hemorrhage in congenital bleeding disorders. Blood Coagul Fibrinolysis. 2017. \n                    https:\/\/doi.org\/10.1097\/MBC.0000000000000660\n                    \n                  .","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2434_CR6","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1538-7836.2006.01776.x","volume":"4","author":"C Mejia-Carvajal","year":"2006","unstructured":"Mejia-Carvajal C, Czapek EE, Valentino LA. Life expectancy in hemophilia outcome. J Thromb Haemost. 2006;4:507\u20139.","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"2434_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1365-2516.2008.01946.x","volume":"15","author":"J Oldenburg","year":"2009","unstructured":"Oldenburg J, Dolan G, Lemm G. Haemophilia care then, now and in the future. Haemophilia. 2009;15(Suppl 1):2\u20137.","journal-title":"Haemophilia"},{"key":"2434_CR8","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/j.1365-2141.2009.08005.x","volume":"148","author":"M Franchini","year":"2010","unstructured":"Franchini M, Mannucci PM. Co-morbidities and quality of life in elderly persons with haemophilia. Br J Haematol. 2010;148:522\u201333.","journal-title":"Br J Haematol"},{"issue":"Suppl 77","key":"2434_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/ejh.12497","volume":"94","author":"M Canaro","year":"2015","unstructured":"Canaro M, Goranova-Marinova V, Berntorp E. The ageing patient with haemophilia. Eur J Haematol. 2015;94(Suppl 77):17\u201322.","journal-title":"Eur J Haematol"},{"key":"2434_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1160\/TH08-02-0117","volume":"100","author":"C N\u00e9grier","year":"2008","unstructured":"N\u00e9grier C, Shapiro A, Berntorp E, Pabinger I, Tarantino M, Retzios A, et al. Surgical evaluation of a recombinant factor VIII prepared using a plasma\/albumin-free method: efficacy and safety of Advate in previously treated patients. Thromb Haemost. 2008;100:217\u201323.","journal-title":"Thromb Haemost"},{"key":"2434_CR11","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1046\/j.1365-2516.2002.00635.x","volume":"8","author":"A Batorova","year":"2002","unstructured":"Batorova A, Martinowitz U. Continuous infusion of coagulation factors. Haemophilia. 2002;8:170\u20137.","journal-title":"Haemophilia"},{"key":"2434_CR12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1046\/j.1365-2141.2000.02226.x","volume":"110","author":"A Batorova","year":"2000","unstructured":"Batorova A, Martinowitz U. Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery. Br J Haematol. 2000;110:715\u201320.","journal-title":"Br J Haematol"},{"key":"2434_CR13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1046\/j.1365-2516.2002.00650.x","volume":"8","author":"D Dingli","year":"2002","unstructured":"Dingli D, Gastineau DA, Gilchrist GS, Nichols WL, Wilke JL. Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates. Haemophilia. 2002;8:629\u201334.","journal-title":"Haemophilia"},{"key":"2434_CR14","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1160\/TH14-10-0826","volume":"113","author":"K Fischer","year":"2015","unstructured":"Fischer K, Lassila R, Peyvandi F, Calizzani G, Gatt A, Lambert T, et al. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project. Thromb Haemost. 2015;113:968\u201375.","journal-title":"Thromb Haemost"},{"key":"2434_CR15","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1365-2141.2004.05168.x","volume":"127","author":"NS Key","year":"2004","unstructured":"Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol. 2004;127:379\u201391.","journal-title":"Br J Haematol"},{"key":"2434_CR16","unstructured":"http:\/\/www.jpma.or.jp\/english\/parj\/pdf\/2015.pdf\n                    \n                  ."},{"key":"2434_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/hae.12518","volume":"21","author":"E Santagostino","year":"2015","unstructured":"Santagostino E, Lentz SR, Misgav M, Brand B, Chowdary P, Savic A, et al. Safety and efficacy of turoctocog alfa (NovoEight\u00ae) during surgery in patients with haemophilia A: results from the multinational GuardianTM clinical trials. Haemophilia. 2015;21:34\u201340.","journal-title":"Haemophilia."},{"key":"2434_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1160\/TH15-10-0780","volume":"116","author":"JN Mahlangu","year":"2016","unstructured":"Mahlangu JN, Ragni M, Gupta N, Rangarajan S, Klamroth R, Oldenburg J, et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thromb Haemost. 2016;116:1\u2013203.","journal-title":"Thromb Haemost"},{"key":"2434_CR19","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2491\/jjsth.24.619","volume":"24","author":"T Fujii","year":"2013","unstructured":"Fujii T, Amano K, Atsumi T, Ishiguro A, Ohira K, Okamoto K, et al. Treatment guideline for hemophilia without inhibitor: 2013 update. Japanese J Thromb Hemost. 2013;24:619\u201339.","journal-title":"Japanese J Thromb Hemost"},{"key":"2434_CR20","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1055\/s-0029-1245105","volume":"35","author":"SC Gouw","year":"2009","unstructured":"Gouw SC, van den Berg HM. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment. Semin Thromb Hemost. 2009;35:723\u201334.","journal-title":"Semin Thromb Hemost"},{"key":"2434_CR21","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1071059","volume":"296","author":"P Matzinger","year":"2002","unstructured":"Matzinger P. The danger model: a renewed sense of self. Science. 2002;296:301\u20135.","journal-title":"Science"},{"key":"2434_CR22","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1111\/j.1538-7836.2011.04467.x","volume":"9","author":"CL Eckhardt","year":"2011","unstructured":"Eckhardt CL, van der Bom JG, van der Naald M, Peters M, Kamphuisen PW, Fijnvandraat K. Surgery and inhibitor development in hemophilia A: a systematic review. J Thromb Haemost. 2011;9:1948\u201358.","journal-title":"J Thromb Haemost"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-018-2434-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2434-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2434-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T20:38:32Z","timestamp":1553719112000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-018-2434-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,28]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["2434"],"URL":"https:\/\/doi.org\/10.1007\/s12185-018-2434-2","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,28]]},"assertion":[{"value":"25 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Keiji Nogami has received grants from Baxalta and funding for research from Baxalta, Bayer, Novo Nordisk, Bioverativ, Chugai, and honoraria from Baxalta, Bayer, Novo Nordisk, Bioverativ, CSL Behring, and Chugai outside the submitted work. Hideyuki Takedani has received honoraria from Baxalta\/Shire, Bayer, Biogen, Bioverativ, Chugai Pharmaceutical, CSL Behring, Kaketsuken, Novo Nordisk, and Pfizer and has received a grant from CSL Behring. Midori Shima has received personal fees and grants from Baxalta Bayer, Novonordisk, CSL Behring, Chugai, and Pfizer; personal fees from Bioverativ and Roche; grants from Kaketsuken outside the submitted work. Akira Yoshioka has received honoraria from Baxalta, Japan Red Cross, Daiichi Sankyo, and Bayer outside the submitted work. Tadashi Matsushita has received personal fees from Baxalta for the submitted work, grants and personal fees from Bayer, Baxalta, Novo Nordisk, Kaketsuken, and Biogen-idec outside the submitted work. Junki Takamatsu has declared no conflict of interest. Masashi Taki is an advisory board member for Bioverativ, Chugai, CSL Behring, and Novo Nordisk and an investigator in clinical trials conducted by Baxalta\/Shire, Bioverativ, Chugai, CSL Behring, Novo Nordisk, and Octapharma; has received research supports from CSL Behring and speaker\u2019s fee from Baxalta\/Shire, Bayer, Bioverativ, Novo Nordisk, and Pfizer. Katsuyuki Fukutake has received grants and personal fees from Baxalta outside the submitted work and holds concurrent posts as a professor for the Department of Molecular Genetics of Coagulation Disorders supported by CSL Behring without additional salary; is an advisory committee member of Chugai Pharmaceutical, and consultant of Chugai Pharmaceutical; has received research funding from Bayer, Biogen\/Bioverativ, Kaketsuken, Novo Nordisk, and Pfizer; has received honoraria for consulting, speaking or advising from Bayer, Biogen\/Bioverativ, Chugai Pharm.\/Roche, CSL Behring, Japan Blood Products, Kaketsuken, MSD, Novo Nordisk, Octapharma, and Pfizer. Akira Shirahata has declared no conflict of interest. Werner Engl, Haruhiko Uchikawa, Hiroshi Takagi, and Morio Arai are full-time employees of Shire (formerly Baxalta).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}